Non-alcoholic fatty liver disease, cytokeratin-18, and risk of type 2 diabetes mellitus: A cohort study

CURRENT STATUS: POSTED

Ruofan Hu
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University

Shaoyong Xu
Department of Endocrinology, XiangYang Central Hospital of HuBei University of Arts and Science

Han Shen
Department of Internal Medicine, Beijing Sijiqing Hospital

Ce Jing
Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University

Aihua Jia
Department of Endocrinology, The first Hospital of YuLin, Shannxi

Xinwen Yu
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University

Ying Xing
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University

Shengru Liang
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University

Jie Ming
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University

Qiuhe Ji qiuheji@hotmail.com
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University

Corresponding Author
ORCiD: 0000-0002-4008-2974

DOI:
10.21203/rs.2.16214/v1

SUBJECT AREAS
KEYWORDS
non-alcoholic fatty liver disease; type 2 diabetes mellitus; cohort study; population-based study; oral glucose tolerance test; cytokeratin-18
Abstract

Background & Aims: Although many studies have shown that non-alcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM), no cohort study has explored the relationship between the histopathological grade of NAFLD and the risk of T2DM in NAFLD patients. We aimed to explore whether a higher concentration of cytokeratin-18 (CK-18), as a reliable marker of hepatic fibrosis, was associated with a greater risk of T2DM in patients with NAFLD. Methods: The population-based cohort study was based on China National Diabetes and Metabolic Disorders Survey with a follow-up of five years. NAFLD was determined by ultrasonography. T2DM were diagnosed based on oral glucose tolerance test. Serum CK-8 was measured using the M30 Apoptosense ELISA kit. Results: 457 subjects were enrolled and three groups were analyzed: a non-NAFLD group (n=363), a low-CK-18 NAFLD group (n=46), and a high-CK-18 NAFLD group (n=48). 20 (3.9%) developed diabetes during follow-up. The incidence of T2DM was 2.5%, 8.7%, and 12.5% in the non-NAFLD, low-CK-18 NAFLD, and high-CK-18 NAFLD groups, respectively. Cox proportional hazard regression showed that, compared with the non-NAFLD group, the adjusted relative risks of T2DM were 3.37 (95% CI: 1.05-10.86, P =0.042) and 4.71 (95% CI: 1.71-12.99, P =0.003), respectively, in the low-CK-18 NAFLD and high-CK-18 NAFLD groups. Conclusions: Higher CK-18 level in ultrasound-diagnosed NAFLD patients is associated with higher risk of T2DM. We recommend screening for NAFLD using ultrasound in the first instance, with, if possible, CK-18 assay being subsequently used to screen individuals at higher risk of diabetes.

Background

Non-alcoholic fatty liver disease (NAFLD) has become one of the most important diseases affecting public health in the twenty-first century, with an estimated worldwide prevalence
of 25% [1]. It is characterized by significant lipid deposition in the hepatocytes of patients in the absence of other etiologies, including excessive alcohol use, poisoning, or viral infection [1–3]. Although many studies have shown that NAFLD is associated with type 2 diabetes mellitus (T2DM), and some studies suggest that insulin resistance is an important mechanism [4,5], no cohort study has yet explored the relationship between the histopathological grade of NAFLD and the risk of T2DM in NAFLD patients.

The level of cytokeratin-18 (CK-18), an intermediate product of protein metabolism in the liver, is thought to reflect the degree of hepatocyte apoptosis that occurs during the development of non-alcoholic steatohepatitis (NASH) and to show a close relationship with the degree of NASH inflammation and hepatic fibrosis. However, the correlation between serum levels of CK18, which is a biomarker of hepatic cell damage, and T2DM is less investigated. In a 2015 pilot study that covered the relationship between CK-18 level and T2DM [6], NAFLD patients who developed T2DM had significantly higher baseline CK-18 levels than those who did not develop T2DM. This suggests that measurement of CK-18 could be a useful marker for the development of T2DM in the NAFLD population. However, a relatively small patient sample was studied, so the findings may have been affected by selection bias. Another study supported the idea of an independent relationship between T2DM and cytokeratin-18 by establishing a significant positive association between fasting plasma glucose and serum cytokeratin-18 concentration, and this correlationship was not found to be related to the existence of NAFLD. However, the study was conducted in patients with T2DM, with fewer samples and only 244 cases. The relationship between T2DM and CK18 is not strong enough [7]. Large-scale population studies in NAFLD patients are warranted to validate the findings of these two experiments.

The purpose of this study was to determine whether a higher concentration of circulating CK-18 in patients with NAFLD is associated with a greater risk of T2DM.
Methods

Study population

We conducted a cohort study that enrolled subjects for a period of at least five years, and was based on the findings of the China National Diabetes and Metabolic Disorders Survey (CNDMDS) (2007-2008). The baseline study was completed between August 2007 and June 2008, and the follow-up study was completed between June 2012 and October 2013. On each occasion, the subjects completed the same questionnaire. One thousand nine hundred and fifteen subjects in the CNDMDS from the Xi’an area (including the city, counties, townships, and villages) of Shaanxi Province were recruited, and 806 subjects (42.1%) agreed to participate in the study and completed the follow-up questionnaire. Of these, subjects with T2DM diagnosed by oral glucose tolerance test (OGTT) or self-reported T2DM (n=75), pre-diabetes (n=172), excessive alcohol use (n=39), those missing key data (n=10), and those suspected to be secondary to liver cirrhosis or suspicion of malignancy (n=2) were excluded. In addition, individuals with missing CK-18 values (n=35) or those with outlying serum CK-18 values (n=16) were also excluded. Thus, data from 457 subjects were analyzed. The research protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Medical Ethics Committee of Xijing hospital, Fourth Military Medical University. All subjects signed their informed consent prior to the start of the study.

Data collection

Data regarding demographics, personal history, family history, and lifestyle were collected using a standardized questionnaire by doctors or nurses who had received uniform training. Current smokers were defined as persons who reported smoking at least 100 cigarettes during their lifetime; alcohol use was defined as an intake of least 30 g of alcohol monthly within a year; and regular physical exercise was defined as undertaking
physical activities at least three times per week, for at least 30 min on each occasion. In addition, data concerning social status, educational level, occupation, and income were also collected.

Anthropometric measurements were performed by specially assigned personnel. Subjects removed their shoes and socks and wore light clothing for the measurement of their height and weight. Body mass index (BMI) was calculated as body weight (kg)/ height (m)$^2$. For the measurement of waist circumference, subjects were asked to stand with their body weight equally distributed, and it was undertaken using a tape measure placed horizontally around the abdomen at the midpoint of the line between anterior superior iliac spine and the lower edge of the twelfth rib. The waist circumference measurement obtained was accurate to 0.1 cm. A mercury desk sphygmomanometer was used to measure blood pressure twice in the right upper arm after at least 5 min rest. All subjects were fasted for at least 8 h, then subjects without a history of diabetes underwent a 75-g oral glucose tolerance test, whereas those with a history of diabetes underwent a steamed bread meal test, for safety reasons. Fasting blood samples were collected for the measurement of triglyceride, high-density lipoprotein, low-density lipoprotein, total cholesterol, and insulin.

**CK-18 measurement**

Serum CK-18 was measured in 806 subjects using the M30 Apoptosense ELISA (Apoptosis Biomarker Assay) kit (Peviva, Stockholm, Sweden) and a Molecular Devices Tecan Spectra Max 190 Microplate Devices (Tecan Trading AG, Switzerland).

**Definitions**

Diabetes mellitus (DM): The 1999 World Health Organization (WHO) criteria for diabetes and pre-diabetes were applied [8]: a) Diabetes: fasting blood glucose (FBG) ≥ 7.0 mmol/L, OGTT 2-hour postprandial glucose (PPG) ≥ 11.1 mmol/L, or self-reported use of
hypoglycemic medications. b) Pre-diabetes: impaired fasting glucose (IFG): 6.1 ≤ FBG < 7.0 mmol/L; and impaired glucose tolerance (IGT): 7.8 ≤ 2h-PPG < 11.1 mmol/L. Patients with IFG or IGT were collectively referred to as having impaired glucose regulation, also known as pre-diabetes. 3) Normal blood sugar: diabetes was ruled out if FBG < 5.6 mmol/L and OGTT 2h-PPG < 7.8 mmol/L.

NAFLD: NAFLD was diagnosed if it met two of the following three criteria, after ruling out excessive alcohol use or the presence of other etiological factors: a) ultrasound examination showed diffuse enhancement of near-field echo in the hepatic region ("bright liver"), with the echo being stronger than that of the kidneys; b) the intrahepatic ductal structures were not clearly visible; and c) the far-field echo in the hepatic region gradually became attenuated [9].

**Statistical analysis**

Data were analyzed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). Data are presented as mean ± standard deviation (SD) or median (interquartile ranges). Comparisons between two groups were conducted using Student’s t test or the rank sum test. Count data are presented using rates or percentages, and inter-group comparisons were made using the chi-square test. Serum CK-18 was not normally distributed and is therefore presented as median (interquartile range); however, the data became normally distributed after logarithmic transformation. Based on their median CK-18 values, the NAFLD subjects were divided into two groups: a high-CK-18 NAFLD group and a low-CK-18 NAFLD group. The risks of NAFLD and T2DM were calculated using a Cox proportional hazards regression model; the relative risk and 95% confidence intervals were calculated using the stepwise regression method. The covariates used in the multivariate analysis were baseline age (continuous variable),
gender, educational level, smoking, drinking, sports history, family history of diabetes, BMI (continuous variable), blood pressure (continuous variable), FBG (continuous variable), 2h-PPG (continuous variable), serum TG (continuous variable), and HDL cholesterol (continuous variable). A two-sided test was used, with $P < 0.05$ being considered statistically significant.

Results

Of the 1915 subjects who participated in the baseline study, 806 subjects (42.1%) agreed to participate in and completed the follow-up study five years later. Based on the above inclusion criteria, 457 subjects were enrolled in this cohort study. Subjects were divided into a NAFLD group and a non-NAFLD group, based on ultrasound diagnosis of fatty liver. According to their median CK-18 levels, subjects in the NAFLD group were further divided into high-CK-18 NAFLD and low-CK-18 NAFLD groups. Thus, three groups were analyzed: a non-NAFLD group (n=363), a low-CK-18 NAFLD group (n=46), and a high-CK-18 NAFLD group (n=48). These three groups showed no significant differences in age, gender, smoking history, sports history, and family history of diabetes. However, the NAFLD groups had significantly higher BMI, systolic blood pressure, diastolic blood pressure, FBG, TG, and HDL cholesterol levels than the non-NAFLD group (all $P<0.001$) (Table 1).

Serum CK-18 level at baseline was 125.3 U/L (95% CI: 57.3-476.6 U/L), and the data distribution is shown in Figure 1. Serum CK-18 was 235.9 U/L (167.3-392.5 U/L) in the high-CK-18 NAFLD group, which was significantly higher than in the non-NAFLD group (120.6 U/L; 87.6-186.3 U/L) ($P < 0.001$). However, serum CK-18 was not significantly different between the low-CK-18 NAFLD (105.2 U/L; 75.6-116.9 U/L) and non-NAFLD groups ($P=0.068$) (Figure 2).

After 5 years of follow-up, 19 of the 457 subjects had developed diabetes. The incidence of T2DM was 2.5%, 8.7%, and 12.5% in the non-NAFLD, low-CK-18 NAFLD, and high-CK-18
NAFLD groups, respectively (Figure 3).

The Cox proportional hazard regression model showed that, compared with the non-NAFLD group, the relative risks (RRs) of T2DM, after adjustment with multiple variables, were 3.37 (95% CI: 1.05-10.86, $P=0.042$) and 4.71 (95% CI: 1.71-12.99, $P=0.003$), respectively, in the low-CK-18 NAFLD and high-CK-18 NAFLD groups (Table 2).

Discussion

In this population-based cohort study, the 5-year risk of T2DM was higher in patients with NAFLD. In addition, among subjects with ultrasound-diagnosed NAFLD, higher serum CK-18 was associated with a higher risk of T2DM, with RRs of 3.37 (95% CI: 1.05-10.86) and 4.712 (95% CI: 1.71-12.99) in the low-CK-18 NAFLD and high-CK-18 NAFLD groups, respectively.

This study represented a follow-up to our previous study [10], in which the risk of T2DM was shown to be significantly increased in a Chinese population with NAFLD, and NAFLD was shown to be an independent predictor of T2DM [10]. The findings of this earlier study were consistent with other previous studies [11-23], demonstrating the association between NAFLD and the risk of T2DM. However, all the previous studies (including our own) failed to investigate whether a higher pathological grade of NAFLD is associated with a higher risk of T2DM in NAFLD patients.

In the present study, we have shown that higher CK-18 levels in ultrasound-diagnosed NAFLD patients are associated with a relatively higher risk of T2DM. Nagpal et al. generated similar findings in a pilot study to assess whether baseline CK-18 levels in NAFLD patients diagnosed by hepatic biopsy could predict the future development of diabetes [6]. In their study, the American Diabetes Association (ADA) criteria were used for the diagnosis of diabetes and baseline CK-18 levels were measured using an apoptosis assay kit (ELISA M30-Apoptosense). Thirty-nine patients who met the inclusion criteria
were enrolled, among whom 32 (82.1%) were Caucasians and 20 (51.3%) were female. During the baseline examination, the average age of the study population was 51.3 ± 11.2 years, the average BMI was 33.8 ± 5.6 kg/m^2, and there was an average follow-up period of 62.4 (38.8, 81.0) months. Fourteen patients were diagnosed with diabetes at baseline, and among the remaining 25 patients, 6 (24%) developed diabetes during the follow-up period. The baseline CK-18 level in subjects who developed diabetes was significantly higher than that of the 19 subjects who did not develop diabetes [(768.8 ± 821.5) U/L vs. (285.1 ± 166.5) U/L, P=0.019] [6]. However, the sample size of this pilot study was small (only 25 patients were followed). As a result, the authors were not able to calculate the relative risk of higher CK-18 for diabetes and potential confounding factors could not be adjusted for in their analysis. Furthermore, selection bias might exist in the study population, because the subjects who underwent a liver biopsy might have had more severe NAFLD. In addition, a healthy population without any evidence of NAFLD should ideally also have been included as a control group [24]. Nevertheless, this pilot study was still of interest, because it suggested that baseline serum CK-18 could be used to predict the development of diabetes in patients with NAFLD. In contrast, our current study was a population-based cohort study with a relatively large sample size, but its findings in general corroborate the above assertion.

Our findings also suggest some uncertainty in the pathologic grading of NAFLD provided by ultrasound examination. Although liver biopsy is the gold standard for the diagnosis of NAFLD [25], it is not suitable for large-scale epidemiological studies. Ultrasound is widely used in clinical practice because of its low cost, safety, and high feasibility, and thus it was used in our study for the diagnosis of NAFLD. However, there are some drawbacks to the use of this method. For example, its sensitivity decreases significantly when the liver
fat content is less than 33% or when there is obvious fat accumulation in the abdomen [26-28]. More importantly, it does not permit accurate pathological grading and thus cannot provide information on the degree of NAFLD fibrosis. Previous studies have reported that most NAFLD (especially mild to moderate NAFLD) cases did not have hepatic fibrosis or serious adverse outcomes [29]. Therefore, it is difficult to identify patients with higher pathologic grades among ultrasound-diagnosed NAFLD cases.

CK-18 is an intermediate fragment generated by protein metabolism in liver that is released in greater quantities by apoptotic cells because of the loss of cell matrix integrity [29]. Because CK-18 is mainly produced by caspase 3, which has been found to be active in NASH liver [30], serum CK-18 may be elevated in patients with NASH. This suggests that CK-18 could be used as a biomarker that reflects the degree of NAFLD fibrosis [31-36].

Here, serum CK-18 in the low-CK-18 NAFLD group was not significantly different from that of the non-NAFLD group in a population diagnosed using ultrasound, suggesting that ultrasound may not be ideal for the pathological grading of fibrosis in NAFLD patients. Unlike in the previous study by Nagpal et al. [6], our study did not use liver biopsy to confirm NAFLD, which means that our conclusions must be tentative. The risk of T2DM is significantly higher in NAFLD patients, suggesting that more accurate and non-invasive methods should be found to identify populations at higher risk. Due to its practical advantages, ultrasound has been widely used in clinical settings to screen for fatty liver.

CK-18 measurement, as another non-invasive investigation, may be able to provide additional information to aid the differentiation of NASH patients from the rest of the NAFLD population. Therefore, we recommend screening for NAFLD in the first instance using ultrasound, with CK-18 testing being subsequently used to screen individuals at higher risk of diabetes if possible, so that proactive management may be provided at an earlier stage of the disease. Insulin resistance may be one of the important causes which
lead to the higher incidence of DM in NAFLD patients[4,37,38]. Hepatic insulin resistance, which is caused by diacylglycerol-mediated activation of protein kinase C epsilon (PKC+), may be an important factor in the interaction between the NAFLD and T2DM[37]. Therefore, CK-18 has a high predictive value for DM, which may be related to insulin resistance. Our research did not focus on it, and this need further study.

Our study also had onther limitations. First, as described above, although a great deal of effort was expended, the follow-up rate was still relatively low (42.1%), which is a common problem faced by all population-based follow-up studies in China. Second, as a population-based study, most of our subjects had no evidence of liver fibrosis, and the number of subjects was relatively small in the high-CK-18 NAFLD group. Third, since we did not undertake liver biopsies, our study could not define a suitable CK-18 cutoff level to clearly distinguish between NASH and simple NAFLD; thus, we could only use a median value to define the study groups.

In summary, our current study suggests that higher CK-18 level in ultrasound-diagnosed NAFLD patients is associated with higher risk of T2DM. Because both ultrasound and CK-18 determination are non-invasive examinations, we recommend screening for NAFLD using ultrasound in the first instance, with, if possible, CK-18 assay being subsequently used to screen individuals at higher risk of diabetes. This would facilitate proactive management during the early stages of the disease, if required.

Abbreviations

NAFLD: non-alcoholic fatty liver disease; T2DM: type 2 diabetes mellitus; RR: relative risk; CI: confidence interval; CNDMDS: China National Diabetes and Metabolic Disorders Survey; OGTT: oral glucose tolerance test; OR: odds ratio; HDL: high-density lipoprotein; SD: standard deviation; CK-18: cytokeratin-18.
Declarations

Acknowledgments

Not applicable.

Authors’ contributions

We thank all of the physicians and participants of the study for their co-operation and generous participation.

Authors’ contribution: RH, SX and HS contributed equally to the study. QJ, SX and JM conceived and designed the study. RH and SX contributed to the data extraction, performed the analysis and interpreted the results. RH and HS wrote the first draft; AJ, JM, YX and SL contributed to the revision of the final report. All authors read and approved the final manuscript.

Funding

This study was supported by the Chinese Medical Association Foundation and Chinese Diabetes Society. QJ was partly supported by the Natural Science Foundation of Shaanxi Province, China (Grant No. 2013KTZB03-02-01). We also thanks to the Multi-factorial Integrative Management of Type 2 Diabetes (MiDiab) (Grant No. 2017YFC1309803), the Key Research and Development Program of Shan’xi Province, China (Grant No. 2017ZDCXLSF0201)

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments (Ethical code: KY20162099-1).
Consent for publication

Not Applicable

Competing interests

The authors declare that they have no competing interests

Author details

1 Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi’an, China

2 Department of Endocrinology, Xiangyang Central Hospital of Hubei University of Arts and Science, Xiangyang, China

3 Department of Internal Medicine, Beijing SiJiqing Hospital

4 Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China

5 Department of Endocrinology, The First Hospital of Yulin, Shannxi, China

References

[1] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. J Hepatol. 2016;64:73-84; doi.org/10.1002/hep.2016.28431.

[2] De Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1: S104-112; doi.org/10.1016/hep.2008.009.

[3] Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and epatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J Gastroenterol. 2015;21:12989-12995; doi.org/10.3748/wjg.2015.12989.

[4] Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Insulin resistance increases the risk of incident type 2 diabetes
mellitus in patients with non-alcoholic fatty liver disease. Hepatol Res. 2017;48(3):E42-E51; doi.org/10.1111/hepr.12925.

[5] Brouwers B, Schrauwen-Hinderling VB, Jelenik T, Gemmink A, Havekes B, Bruls Y, Dahlmans D, Roden M, Hesselink MKC, Schrauwen P. Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. Clin Sci (Lond). 2017;131(15):1905-1917; doi.org/10.1042/CS20170261.

[6] Nagpal SJ, Lopez R, Feldstein AE, Alkhouri N. Serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD. Liver Int. 2015;35:2621; doi.org/10.1111/liv.2015.12862.

[7] Yu-Hung Chang, Hsien-Chang Lin, Der-Wei Hwu, Dao-Ming Chang, Kun-Chen Lin, Yau-Jiunn Lee. Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Ann Clin Biochem. 2019;56(1):141-147; doi.org/10.1177/0004563218796259.

[8] Alberti KG, Zimmet PZ. Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.

[9] Farrell GC, Chitturi S, Lau GK, Sollano JD. Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepato. 2007;22:775-777.

[10] Jie Ming, Shaoyong Xu, Bin Gao, Guocai Liu, Yufei Ji, Fan Yang, Yunan Jia, Yujie Fang and Qiuhe Ji. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study. Liver Int. 2015;35:2401-2407; doi.org/10.1111/liv.2015.12851.

[11] Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver
disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007;22:1086-1091.

[12] Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008;25:476-481; doi.org/10.1111/j.1464-5491.2008.02410.

[13] Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010;25:352-356; doi.org/10.1111/j.1440-1746.2009.05998.

[14] Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-Kaluski D, Halpern Z, Santo E, Oren R. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013;33:1406-1412; doi.org/10.1111/liv.12200.

[15] Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35:717-722; doi.org/10.2337/dc11-1853.

[16] Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007;30:2940-2944; doi.org/10.2337/doi.2007.7115.

[17] Fukuda T, Hamaguchi M, Kojima T, Mitsuhashi K, Hashimoto Y, Ohbora A, Kato T, Nakamura N, Fukui M. Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men. Eur J Gastroenterol Hepatol. 2016;12:1443-1449; doi.org/10.1097/MEG.0000000000000736.

[18] Heianza Y, Arase Y, Tsuji H, Fujihara K, Saito K, Hsieh SD, Tanaka S, Kodama S, Hara S, Sone H. Metabolically healthy obesity, presence or absence of fatty liver, and risk of
type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). J Clin Endocrinol Metab. 2014;99:2952-2960; doi.org/10.1210/jc.2013.4427.

[19] Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care. 2011;34:727-729; doi.org/10.2337/dc10-1991.

[20] Kotronen A, Laaksonen MA, Heliövaara M, Reunanen A, Tuomilehto J, Yki-Järvinen H, Peltonen M, Knekt P. Fatty liver score and 15-year incidence of type 2 diabetes. Hepatol Int.2013;7:610-621; doi.org/10.1007/s12072-013-9430-7.

[21] Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57:1378-1383; doi.org/10.1002/hep.2013.26183.

[22] Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936–944; doi.org/10.1111/jgh.2016.13264.

[23] Nobili V, Mantovani A, Cianfarani S, Alisi A, Mosca A, Sartorelli MR, Maffeis C, Loomba R, Byrne CD, Targher G. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. J.Hepatol.2019; doi.org/10.1016/j.jhep.2019.06.023

[24] Ming J, Xu S, Gao B, Ji Q. Response to Serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD. Liver Int.
2015;35:2622. https://doi.org/10.1111/liv.2015.12867.

[25] Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-750.

[26] Williamson RM, Perry E, Glancy S, Marshall I, Gray C, Nee LD, Hayes PC, Forbes S, Frier BM, Johnston GI, Lee AJ, Reynolds RM, Price JF, Strachan MW. Edinburgh Type 2 Diabetes Study investigators. The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra- and interobserver variability and comparison with magnetic resonance spectroscopy. Clin Radiol.2011;66:434-439; doi.org/10.1016/j.crad.2010.09.021.

[27] Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 2009;41:265-278; doi.org/10.1080/07853890802552437.

[28] Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009;28:2-12; doi.org/10.1111/j.1365-2036.2008.03710.

[29] Galluzzi L1, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ.2007;14:1237-1243.

[30] Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology.2003;125:437-443.

[31] Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, Nagaya T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Tanaka E, Sano K. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase
levels. J Clin Gastroenterol. 2010;44:440-447; doi.org/10.1097/MCG.0b013e3181bdefe2.

[32] Wieckowska A1, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27-33.

[33] Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol. 2010;13:837-844.

[34] Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, Byrnes V, Afdhal N. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2010;24:564-568.

[35] Mandelia C, Collyer E, Mansoor S, Lopez R, Lappe S, Nobili V, Alkhouri N. Plasma Cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2016;63:181-187; doi.org/10.1097/MPG.0000000000001136.

[36] Arab JP, Hernández-Rocha C, Morales C, Vargas JL, Solís N1, Pizarro M, Robles C, Sandoval D, Ponthus S, Benítez C, Barrera F, Soza A, Riquelme A, Arrese M. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population. Gastroenterol Hepatol. 2017;40:388-394; doi.org/10.1016/j.gastrohep.2017.02.009.

[37] De Silva NMG, Borges MC, Hingorani AD, Engmann J, Shah T, Zhang X, Luan J, Langenberg C, Wong A, Kuh D, Chambers JC, Zhang W, Jarvelin MR, Sebert S, Auvinen J; UCLEB consortium, Gaunt TR, Lawlor DA. Liver Function and Risk of Type 2 Diabetes: Bidirectional Mendelian Randomization Study. Diabetes. 2019;8:1681-1691; doi.org/10.2337/db18-
Tables

Table 1. Baseline data for the study population

| Variables                        | Non-NAFLD group | NAFLD groups | P value |
|----------------------------------|-----------------|--------------|---------|
|                                  |                 | Low-CK-18    | High-CK-18 |
| n                                | 363             | 46           | 48      |
| Demographic data                 |                 |              |         |
| Age (years)                      | 45.2±12.6       | 48.9±12.8    | 46.8±12.5 | 0.147   |
| Gender (Male) [n(%)]             | 155 (42.7)      | 21 (45.7)    | 20 (41.7) | 0.915   |
| Body mass index (kg/m²)          | 23.2±3.1        | 26.0±2.8     | 25.7±4.0* | <0.001  |
| Education level, n (%)           |                 |              |         |
| High school and above            | 305 (85.5)      | 38 (82.6)    | 37 (84.3)* | 0.016   |
| Family history of diabetes, n(%) | 37 (10.2)       | 8 (17.4)     | 7 (14.6)  | 0.267   |
| History of smoking, n(%)         | 64 (17.6)       | 6 (13.3)     | 10 (20.8) | 0.634   |
| History of alcohol use, n (%)    | 55 (15.3)       | 2 (4.4)      | 3 (6.3)   | 0.041   |
| Sport history, n (%)             | 168 (46.4)      | 26 (56.5)    | 17 (35.4) | 0.121   |
| Clinical data                    |                 |              |         |
| Systolic blood pressure (mmHg)   | 118.8±19.2      | 122.0±25.1   | 129.6±21.3* | 0.002   |
| Diastolic blood pressure (mmHg)  | 74.9±11.1       | 76.3±12.1    | 80.4±11.9* | 0.006   |
| Fasting blood glucose (mmol/L)   | 4.9±0.5         | 5.1±0.6      | 5.2±0.6*  | 0.003   |
| 2-hour postprandial blood sugar (mmol/L) | 5.5±1.2        | 5.8±1.1      | 5.8±1.2  | 0.099   |
| Total cholesterol (mmol/L)       | 4.7±0.9         | 4.6±1.0      | 4.8±0.9  | 0.444   |
| Triglycerides (mmol/L)           | 1.3±0.9         | 1.9±1.2      | 1.9±1.7* | <0.001  |
| High-density lipoprotein (mmol/L)| 1.4±0.3         | 1.1±0.3      | 1.2±0.3* | <0.001  |

* P<0.05, non-NAFLD group as ref. NAFLD, non-alcoholic fatty liver disease; CK-18, cytokeratin-18
Table 2. Regression analysis of the relationship between NAFLD and the risk of T2DM, based on the median level of CK-18

| Variables               | Not adjusted | Adjusted* |
|-------------------------|--------------|-----------|
|                         | RR (95% CI)  | P value   | RR (95% CI)  | P value   |
| Non-NAFLD group         | 1.000        |           | 1.000        |           |
| Non-NAFLD group Low-CK-18 NAFLD group | 3.431 (1.076-10.940) | 0.037 | 3.371 (1.047-10.858) | 0.042 |
| High-CK-18 NAFLD group  | 4.825 (1.754-13.276) | 0.002 | 4.712 (1.710-12.987) | 0.003 |

NAFLD: non-alcoholic fatty liver disease; RR: relative risk; CI: confidence interval.

*The relative risk and 95% confidence intervals were calculated using the backward stepwise regression method. The covariates included age, gender, educational level, history of smoking, history of alcohol use, sports history, family history of diabetes, body mass index, blood pressure, blood glucose, triglyceride, and high-density lipoprotein.

Figures
Figure 1

Distribution of baseline CK-18 concentrations in the study population CK-18:

cytokeratin-18
Comparison of CK-18 levels between NAFLD and non-NAFLD groups NAFLD: non-alcoholic fatty liver disease; CK-18: cytokeratin-18
The 5-year incidence of diabetes in each patient group NAFLD: non-alcoholic fatty liver disease; CK-18: cytokeratin-18